These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8047810)

  • 1. Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment.
    Rudi J; Raedsch R; Gerteis C; Schlenker T; Plachky J; Walter-Sack I; Sabouraud A; Scherrmann JM; Kommerell B
    Scand J Gastroenterol; 1994 Apr; 29(4):346-51. PubMed ID: 8047810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/bioavailability of colchicine in healthy male volunteers.
    Achtert G; Scherrmann JM; Christen MO
    Eur J Drug Metab Pharmacokinet; 1989; 14(4):317-22. PubMed ID: 2633927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biliary excretion of colchicine.
    Hunter AL; Klaassen CD
    J Pharmacol Exp Ther; 1975 Mar; 192(3):605-17. PubMed ID: 1120958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fab-bound colchicine appears to adopt Fab fragment disposition in rats.
    Sabouraud AE; Urtizberea M; Benmoussa K; Cano NJ; Scherrmann JM
    J Pharm Pharmacol; 1992 Dec; 44(12):1015-9. PubMed ID: 1361548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
    Hempfling W; Grunhage F; Dilger K; Reichel C; Beuers U; Sauerbruch T
    Hepatology; 2003 Jul; 38(1):196-202. PubMed ID: 12830002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colchicine disposition in patients with familial Mediterranean fever with renal impairment.
    Ben-Chetrit E; Scherrmann JM; Zylber-Katz E; Levy M
    J Rheumatol; 1994 Apr; 21(4):710-3. PubMed ID: 8035398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colchicine disposition in human leukocytes after single and multiple oral administration.
    Chappey ON; Niel E; Wautier JL; Hung PP; Dervichian M; Cattan D; Scherrmann JM
    Clin Pharmacol Ther; 1993 Oct; 54(4):360-7. PubMed ID: 8222477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zero-order absorption and linear disposition of oral colchicine in healthy volunteers.
    Thomas G; Girre C; Scherrmann JM; Francheteau P; Steimer JL
    Eur J Clin Pharmacol; 1989; 37(1):79-84. PubMed ID: 2591469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are dosing adjustments required for colchicine in the elderly compared with younger patients?
    Wason S; Faulkner RD; Davis MW
    Adv Ther; 2012 Jun; 29(6):551-61. PubMed ID: 22753019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic copper in primary biliary cirrhosis: biliary excretion and response to penicillamine treatment.
    Salaspuro MP; Pikkarainen P; Sipponen P; Vuori E; Miettinen TA
    Gut; 1981 Nov; 22(11):901-6. PubMed ID: 7308845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of liver dysfunction on colchicine pharmacokinetics in the rat.
    Leighton JA; Bay MK; Maldonado AL; Johnson RF; Schenker S; Speeg KV
    Hepatology; 1990 Feb; 11(2):210-5. PubMed ID: 2307399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary excretion of mezlocillin in patients with hepatic disease.
    Hildebrandt R; Gundert-Remy U; Raedsch R; Sieg A; Stiehl A
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):384-7. PubMed ID: 7582392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers.
    Girre C; Thomas G; Scherrmann JM; Crouzette J; Fournier PE
    Fundam Clin Pharmacol; 1989; 3(5):537-43. PubMed ID: 2606428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of colchicine: a review of experimental and clinical data.
    Sabouraud A; Rochdi M; Urtizberea M; Christen MO; Achtert G; Scherrmann JM
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():35-9. PubMed ID: 1449014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol.
    Bonis PA; Kaplan M
    Gastroenterology; 1999 Aug; 117(2):395-9. PubMed ID: 10419921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis.
    Leung J; Bonis PA; Kaplan MM
    Clin Gastroenterol Hepatol; 2011 Sep; 9(9):776-80. PubMed ID: 21699802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases.
    Rochdi M; Sabouraud A; Baud FJ; Bismuth C; Scherrmann JM
    Hum Exp Toxicol; 1992 Nov; 11(6):510-6. PubMed ID: 1361141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects.
    Rochdi M; Sabouraud A; Girre C; Venet R; Scherrmann JM
    Eur J Clin Pharmacol; 1994; 46(4):351-4. PubMed ID: 7957521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine.
    Sabouraud A; Redureau M; Gires P; Martinet M; Scherrmann JM
    Drug Metab Dispos; 1993; 21(6):997-1002. PubMed ID: 7905405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.